A Reduced-carbohydrate Diet High in Monounsaturated Fats in Type 2 Diabetes

Atherosclerosis Clinical Trial

— ReDuCtion  

Official title:

A Reduced-carbohydrate Diet High in Monounsaturated Fats in Type 2 Diabetes: a Six-month Study of Changes in Metabolism, Liver- and Cardiovascular Function (ReDuCtion)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03068078
• Other study ID #: S-20150217
• Status: Completed
• Phase: N/A
• Start date: November 2016
• Est. completion date: June 4, 2021

Study information

• Verified date: July 2021
• Source: Odense University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Further studies are needed to establish the optimal diet for treating T2D. The investigators wishes to investigate whether a low carbohydrate diet, high in monounsaturated fats (LCD) will affect cardiovascular function, metabolism and the liver. 135 participants with T2D, will be following either a LCD, or a regular diabetes diet (RDD) for 6 months. Measurements and investigations will be performed at baseline and after 6 months.

Description:

Type 2 diabetes (T2D) is an increasing global problem, especially in developing countries. T2D is associated with an increased risk of cardiovascular disease (CVD), where hyperglycemia is especially important for microvascular damage. Previous studies in T2D on reduced carbohydrate intake has shown beneficial effects on glycemic control, indicated by reduction in HbA1c, fasting insulin and 2h-glucose (OGTT) values. However further studies are needed to establish the optimal diet for treating T2D. The investigators wishes to investigate whether a low carbohydrate diet, high in monounsaturated fats will: 1. Improve glycemic control, dyslipidemia and metabolic markers in T2D despite unchanged anti-diabetic treatment. 2. Improve endothelial function assessed by flow-mediated vasodilation (FMD) in the brachial artery as well as microvascular damage assessed by retinal scan, urine albuminuria and minimal forearm vascular resistance (MFVR). 3. Improve Non-Alcoholic Fatty Liver Disease (NAFLD) assessed by >2 points reduction in NAFLD Activity score with at least 1 point reduction in either lobular inflammation or hepatocellular ballooning, without worsening of fibrosis. 4. Improve quality of life 5. Improve gut dysbiosis The study will be conducted through a 6 month randomized controlled trial with 135 participants with type 2 diabetes. 90 participants will be randomized to the intervention group, following a LCD, and 45 participants will be randomized to the control group (regular diet for diabetes, RDD). The below described measurements will be conducted before baseline and after 6 months, and the participants will fill out a QoL questionnaire at 0, 3 and 6 months. Planned examinations are ultrasound assessment of flow-mediated vasodilation, Dual-energy X-ray absorptiometry (DEXA-scan), retina scan, liver biopsy, liver-scans, blood, urine, hair, saliva and feces. Accelerometers will be applied before, during and after the study to evaluate compliance in unchanged exercise pattern. Compliance with diet will be evaluated by a clinical dietitian and through food diaries. Baseline histology from the first 50 participants suggest that the current inclusion criteria doesn't cover the full spectrum of NAFLD (NASH and fibrosis) as expected. Further 50 participants who will have had diabetes for more than 10 years and who will not fulfill inclusion criteria number 1 and 2 will be included. On this group of participants we will only perform liver-investigations and DEXA-scan. This group of participants, will not affect the timeschedule of the main study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 185
• Est. completion date: June 4, 2021
• Est. primary completion date: June 4, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Duration of established T2D for more than six months and less than five years and HbA1c in compliance with T2D (above 48 mmol/mol), but without need for adjustment of antidiabetic treatment*

2. Serum cholesterol below 4.5 mmol/l and LDL cholesterol below 2.5 mmol/l at inclusion**

3. Age of 18 or above

4. Stable diabetic treatment three months prior to inclusion***

5. Be able to read and understand Danish language

6. Signed written consent

• based on the assumption that metabolic and cardiovascular changes are less likely to be reversible in patients with longstanding T2D. HbA1c and need for adjustment and if the patient is eligible for inclusion will be evaluated individually based on the patients current treatment and current HbA1c by the project responsible. If the patient has duration of diabetes > 5 years but with current treatment = 2 oral antidiabetic drugs and without insulin treatment, the patient will be accepted for enrolment.
• To avoid changes in lipid-lowering treatment during follow-up total cholesterol should be below 4.5 mmol/l and LDL cholesterol below 2.5 mmol/l at inclusion. Higher levels may be accepted if the patient cannot tolerate lipid-lowering treatment ***Patients can be enrolled three months after medication change

Exclusion Criteria:

1. Low carbohydrate diet prior to inclusion

2. Hypoglycemic unawareness

3. Excessive weight loss within the last three months, defined as more than 10 kilograms

4. Current treatment with glucocorticoids (systemic)

5. Continuous treatment with steatosis-inducing drugs (e.g. carbamazepine)

6. Treatment with antibiotics up to 2 months before inclusion*

7. Treatment with chemotherapy

8. Pregnancy or expected pregnancy within the next 6 months

9. Active alcohol overuse**

10. Active cancer

11. Significant co morbidity including liver disease

12. Poor compliance *Participants can be rescheduled to be included 2 months after use of antibiotics ** Prior alcohol overuse and eligibility will be evaluated individually

Related Conditions & MeSH terms

• Atherosclerosis
• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Dyslipidemias
• Fatty Liver
• Liver Diseases
• Non-alcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis
• Type2 Diabetes

Intervention

Dietary Supplement:
• Low carbohydrate diet high in monounsaturated fats
Participants will have to change their diet during 6 months

Locations

Country	Name	City	State
Denmark	Odense University Hospital	Odense

Sponsors (6)

Lead Sponsor	Collaborator
Odense University Hospital	Danish Diabetes Academy, Novo Nordisk A/S, Odense Patient Data Explorative Network, Region of Southern Denmark, University of Southern Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Glycemic control, dyslipidemia and metabolic markers	Measured by HbA1c, serum cholesterol, blood glucose and metabolic markers	Change from baseline at 6 months
Secondary	Endothelial function	assessed by FMD in the brachial artery as well as microvascular damage assessed by retinal scan, urine albuminuria and minimal forearm vascular resistance (MFVR).	Change from baseline at 6 months
Secondary	Non-Alcoholic Fatty Liver Disease (NAFLD)	Assessed by >2 points reduction in NAFLD Activity score with at least 1 point reduction in either lobular inflammation or hepatocellular ballooning, without worsening of fibrosis.	Change from baseline at 6 months
Secondary	Quality of life	Assessed by questionaire	Change from baseline at 6 months
Secondary	Gut dysbiosis	Assessed by fecal sample	Change from baseline at 6 months